Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

BACKGROUND: Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Health Qual Life Outcomes
Auteurs principaux: Reynolds, Shannon L., Ghate, Sameer R., Sheer, Richard, Gandhi, Pranav K., Moretz, Chad, Wang, Cheng, Sander, Stephen, Costantino, Mary E., Annavarapu, Srinivas, Andrews, George
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5480105/
https://ncbi.nlm.nih.gov/pubmed/28637460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12955-017-0705-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires